<span item_type="fundamental" item_id="eaa1298168e656f96cf92bcb741cb38c" counter_id="ST/US/RAPP" env="prod"></span><span item_type="announcement" item_id="546771880988053377" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -0.75, beating the estimate of USD -0.846.</p><p></p><h3>Net Loss</h3><ul><li>Net loss for the second quarter of 2025 was $26.7 million, compared to $18.1 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2012593/000095017025104557/rapp-ex99_1.htm"></span></li></ul><h3>Research and Development (R&amp;D) Expenses</h3><ul><li>R&amp;D expenses were $22.7 million for the second quarter of 2025, up from $15.7 million in the prior year period. The increase was primarily due to operational costs related to clinical development and pipeline progression.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2012593/000095017025104557/rapp-ex99_1.htm"></span></li></ul><h3>General and Administrative (G&amp;A) Expenses</h3><ul><li>G&amp;A expenses were $6.8 million for the second quarter of 2025, compared to $5.1 million for the same period in 2024. The increase was mainly driven by costs associated with business growth and public company operations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2012593/000095017025104557/rapp-ex99_1.htm"></span></li></ul><h3>Cash Position</h3><ul><li>The company ended the second quarter with $260.4 million in cash, cash equivalents, and short-term investments, down from $285.4 million as of March 31, 2025. The decrease was primarily due to cash outflows from operating activities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2012593/000095017025104557/rapp-ex99_1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities was - $25.1 million for the three months ended June 30, 2025, compared to - $16.4 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2012593/000095017025104557/rapp-ex99_1.htm"></span></li></ul><h3>Cash Runway</h3><ul><li>The company expects its cash, cash equivalents, and short-term investments as of June 30, 2025, to fund operations through the end of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2012593/000095017025104557/rapp-ex99_1.htm"></span><span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/2012593/000095017025104557/rapp-ex99_2.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Rapport Therapeutics anticipates reporting topline results from the Phase 2a trial of RAP-219 in patients with drug-resistant focal onset seizures in September 2025. The company has also initiated a Phase 2 trial of RAP-219 in bipolar mania, with results expected in the first half of 2027. Additionally, plans for a Phase 2a trial in diabetic peripheral neuropathic pain are being finalized, with an update expected in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2012593/000095017025104557/rapp-ex99_1.htm"></span><span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/2012593/000095017025104557/rapp-ex99_2.htm"></span></li></ul>

Rapport Therapeutics | 8-K: FY2025 Q2 EPS Beats Estimate at USD -0.75